Orthobond Corp — SEC Form D Filing
Orthobond Corp filed an SEC Form D on August 31, 2026, reporting $8.35M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 31, 2026
- Amount reported
- $8.35M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://orthobond.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Medical device contamination leads to serious complications, including device failure, pain, and potentially revision surgery, amputation, or death for patients. This issue, often caused by microbes, remains a significant challenge despite existing infection prevention measures.
Solution
Orthobond develops proprietary antimicrobial nanosurfaces that can be permanently bound to medical device surfaces, mechanically rupturing and killing bacteria, viruses, and fungi without using antibiotics or eluting chemicals. Their technology, including Ostaguard™, aims to protect implantable devices and reduce microbial contamination.
Why now
There is a heightened global awareness and focus on pathogen control and surface sanitation, driven by recent public health crises and the increasing need for effective antimicrobial solutions in various industries.
Verdict
This cleared because investors bet on a novel materials science platform addressing a persistent and high-stakes problem in medical devices, not because the go-to-market strategy for specific applications was fully de-risked. The implicit wager was that the core antimicrobial nanosurface technology could achieve regulatory approval and adoption within established medical device manufacturing workflows. Upside was limited by the long development cycles and high capital requirements inherent in medical device commercialization, which often outpace early-stage capital.
Source: SEC EDGAR Form D filing